Search results
12 lip 2024 · This guidance document provides recommendations to clinicians for treatment of infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa).
- Infection Prevention & Control
IDSA/SHEA: Primer on Healthcare Epidemiology, Infection...
- Guideline Development Process
Because of the large number of clinical practice guidelines...
- Ebola
What is Ebola? Ebola virus disease is a severe illness that...
- Evaluation and Management Services
Dr. Timothy Sullivan, Vice Chair of IDSA’s Coding & Payment...
- Bio-Preparedness Workforce Pilot
Once funded, the pilot will create a new loan repayment...
- Lyme Disease
IDSA engages in advocacy efforts that support better Lyme...
- ID Match
The IDSA ID Match Resolution provides guiding principles for...
- Hepatitis C
Viral hepatitis is a silent epidemic. According to the...
- Infection Prevention & Control
19 kwi 2022 · In the present document, guidance is provided on the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) .
27 paź 2020 · This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).
7 sie 2024 · This guidance document focuses on infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), AmpC β- lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR P. aeruginosa), carbapenem-resistant Acinetobacter ...
25 sie 2022 · The initial guidance document on infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) was published on 17 September 2020.
18 kwi 2022 · Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
8 gru 2014 · This systematic review seeks to identify evidence for the effectiveness of targeted infection control measures to control the spread and transmission of ESBL-E when transferring patients between healthcare settings, especially when the transfer is cross-border.
